Immunic Inc. Receives Notice of Allowance for U.S. Patent on Vidofludimus Calcium Dose Strengths in Progressive Multiple Sclerosis
Immunic, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent on dose strengths of vidofludimus calcium (IMU-838) for treating progressive multiple sclerosis. The patent protection is expected to last until 2041, with potential extensions, following positive phase 2 trial results indicating the drug's ability to slow disease progression.
Immunic, Inc. announced it has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled “Treatment of multiple sclerosis comprising DHODH inhibitors.” This patent covers dose strengths associated with vidofludimus calcium (IMU-838) for the treatment of progressive multiple sclerosis (PMS), including primary and secondary progressive forms. The protection is expected to last until 2041, with potential for further extension. This development follows positive phase 2 trial results showing the drug’s potential to slow disease progression in multiple sclerosis patients. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY67323) on September 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
